Skepticism Greets Rare Disease Drug Maker CANbridge in Hong Kong IPO
Company’s shares tumble 27% in trading debut a week ago, but have stabilized since then on hopes for strong growth of China’s market for drugs to treat rare diseases Key…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Why JL Mag came unstuck, but is getting back on track
6680.HK 300748.SHE
-
Everest reaches new heights on growing drug sales
1952.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
